Swiss contract drug manufacturer PolyPeptide is attracting takeover interest from private equity firms including EQT and KKR, Bloomberg News reports, citing sources familiar with the matter. Advent is also reportedly evaluating a potential deal, and any prospective buyer may seek to partner with majority shareholder Frederik Paulsen.
The company, which develops and manufactures synthetic peptides for treatments including obesity and diabetes, is valued at approximately 1 billion Swiss francs following a share price increase of nearly 20 percent this year.
While discussions are ongoing, no deal is guaranteed, according to the sources.